Stem cell treatments for Asia

Israeli biotech Pluristem has been awarded two new patents in Hong Kong for two products – mesenchymal stem cells for the treatment of skeletal muscle damage or injury, and adherent cells to treat Critical Limb Ischemia and connective tissue regeneration.

https://globenewswire.com/news-release/2017/09/13/1120229/0/en/Pluristem-Strengthens-Its-Position-in-Asia-Awarded-Two-New-Patents-in-Hong-Kong-for-Critical-Limb-Ischemia-and-Muscle-Regeneration.html

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *